P305+P351+P338：IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
Description
Obeticholic acid is a potent
and selective farnesoid X receptor agonist that promotes the
flow of bile in the liver. The drug was approved by the
USFDA for the treatment of the rare chronic liver disease
primary biliary cholangitis (PBC) in combination with
ursodeoxycholic acid (UDCA) in adults with inadequate
response to UDCA or as a single agent therapy in adults
unable to tolerate UDCA. Obeticholic acid was discovered at
the Università de Perugia and developed by Intercept
Pharmaceuticals. Obeticholic acid has also been granted orphan
drug designation for the treatment of primary sclerosing
cholangitis and primary biliary cirrhosis and has received
breakthrough therapy designation for the treatment of patients
with nonalcohol steatohepatitis (NASH) with liver fibrosis.
